Goldman Sachs’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.6M | Sell |
999,786
-168,651
| -14% | -$3.64M | ﹤0.01% | 2363 |
|
|
2025
Q4 | $27.8M | Buy |
1,168,437
+217,848
| +23% | +$4.44M | ﹤0.01% | 2057 |
|
|
2025
Q3 | $12.9M | Buy |
950,589
+302,515
| +47% | +$3.15M | ﹤0.01% | 2715 |
|
|
2025
Q2 | $5.28M | Sell |
648,074
-266,134
| -29% | -$2.27M | ﹤0.01% | 3360 |
|
|
2025
Q1 | $7.18M | Buy |
914,208
+470,755
| +106% | +$5.46M | ﹤0.01% | 3004 |
|
|
2024
Q4 | $6.6M | Sell |
443,453
-259,883
| -37% | -$4.24M | ﹤0.01% | 3181 |
|
|
2024
Q3 | $10.8M | Buy |
703,336
+66,562
| +10% | +$1.05M | ﹤0.01% | 2634 |
|
|
2024
Q2 | $9.7M | Buy |
636,774
+386,461
| +154% | +$6.24M | ﹤0.01% | 2535 |
|
|
2024
Q1 | $4.73M | Sell |
250,313
-341,978
| -58% | -$5.91M | ﹤0.01% | 3139 |
|
|
2023
Q4 | $11.3M | Buy |
592,291
+4,083
| +0.7% | +$65.3K | ﹤0.01% | 2404 |
|
|
2023
Q3 | $10.6M | Sell |
588,208
-9,927
| -2% | -$199K | ﹤0.01% | 2343 |
|
|
2023
Q2 | $12.1M | Sell |
598,135
-206,399
| -26% | -$3.93M | ﹤0.01% | 2267 |
|
|
2023
Q1 | $14.7M | Buy |
804,534
+42,114
| +6% | +$805K | ﹤0.01% | 2073 |
|
|
2022
Q4 | $15.8M | Sell |
762,420
-100,965
| -12% | -$2.78M | ﹤0.01% | 2169 |
|
|
2022
Q3 | $22.6M | Sell |
863,385
-110,747
| -11% | -$2.93M | 0.01% | 1762 |
|
|
2022
Q2 | $24.7M | Buy |
974,132
+727,692
| +295% | +$17.8M | 0.01% | 1724 |
|
|
2022
Q1 | $7.78M | Buy |
246,440
+133,979
| +119% | +$4.49M | ﹤0.01% | 2945 |
|
|
2021
Q4 | $4.55M | Buy |
112,461
+53,609
| +91% | +$2.08M | ﹤0.01% | 3512 |
|
|
2021
Q3 | $2.05M | Sell |
58,852
-357,879
| -86% | -$11.1M | ﹤0.01% | 4178 |
|
|
2021
Q2 | $11.4M | Sell |
416,731
-164,720
| -28% | -$4.7M | ﹤0.01% | 2560 |
|
|
2021
Q1 | $16.3M | Sell |
581,451
-177,712
| -23% | -$6.18M | ﹤0.01% | 2109 |
|
|
2020
Q4 | $19.7M | Buy |
759,163
+304,495
| +67% | +$7.37M | 0.01% | 1873 |
|
|
2020
Q3 | $7.79M | Sell |
454,668
-95,699
| -17% | -$2.14M | ﹤0.01% | 2533 |
|
|
2020
Q2 | $13.6M | Buy |
550,367
+467,011
| +560% | +$12.6M | ﹤0.01% | 2011 |
|
|
2020
Q1 | $1.16M | Sell |
83,356
-39,079
| -32% | -$486K | ﹤0.01% | 3656 |
|
|
2019
Q4 | $1.24M | Buy |
122,435
+28,982
| +31% | +$244K | ﹤0.01% | 3983 |
|
|
2019
Q3 | $850K | Buy |
93,453
+738
| +0.8% | +$5.93K | ﹤0.01% | 4138 |
|
|
2019
Q2 | $737K | Buy |
92,715
+48,563
| +110% | +$486K | ﹤0.01% | 4179 |
|
|
2019
Q1 | $551K | Buy |
44,152
+4,074
| +10% | +$44.2K | ﹤0.01% | 4378 |
|
|
2018
Q4 | $432K | Buy |
40,078
+21,863
| +120% | +$255K | ﹤0.01% | 4443 |
|
|
2018
Q3 | $254K | Sell |
18,215
-10,638
| -37% | -$136K | ﹤0.01% | 4795 |
|
|
2018
Q2 | $353K | Sell |
28,853
-100,172
| -78% | -$1.57M | ﹤0.01% | 4698 |
|
|
2018
Q1 | $1.99M | Buy |
+129,025
| New | +$2.15M | ﹤0.01% | 3605 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Goldman Sachs's RCUS Position: Q1 2026 in Review
Goldman Sachs reduced its Arcus Biosciences (RCUS) stake by 14% in Q1 2026, selling an estimated $3.64M and leaving 999,786 shares worth $21.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2363.
Goldman Sachs first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $27.8M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Goldman Sachs held 999,786 shares of Arcus Biosciences worth $21.6M as of Q1 2026.
- Goldman Sachs sold 168,651 Arcus Biosciences shares in Q1 2026, an estimated $3.64M.
- Arcus Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2363 holding.
- Goldman Sachs first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
- Goldman Sachs's Arcus Biosciences position peaked at $27.8M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.